Drug/drug delivery systems for the prevention and treatment of vascular disease
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61F-002/00
A61F-002/06
출원번호
US-0829074
(2004-04-21)
등록번호
US-7300662
(2007-11-27)
발명자
/ 주소
Falotico,Robert
Kopia,Gregory A.
Llanos,Gerard H.
출원인 / 주소
Cordis Corporation
대리인 / 주소
Woodcock Washburn LLP
인용정보
피인용 횟수 :
21인용 특허 :
398
초록▼
A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal
A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.
대표청구항▼
What is claimed is: 1. A drug delivery device comprising: an intraluminal stent; a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and from about 64 μg to about 197 μg of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into t
What is claimed is: 1. A drug delivery device comprising: an intraluminal stent; a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and from about 64 μg to about 197 μg of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said device provides an in-stent late loss in diameter at 12 months following implantation in a human of less than about 0.5 mm, as measured by quantitative coronary angiography. 2. A drug delivery device according to claim 1 that provides an in-stent late loss in diameter at 12 months following implantation in a human of less than about 0.3 mm, as measured by quantitative coronary angiography. 3. A drug delivery device according to claim 1 or 2 that provides an in-stent diameter stenosis at 12 months following implantation in a human of less than about 22%, as measured by quantitative coronary angiography. 4. A drug delivery device according to claim 3 that provides an in-stent diameter stenosis at 12 months following implantation in a human of less than about 15%, as measured by quantitative coronary angiography. 5. A drug delivery device comprising: an intraluminal stent; a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and from about 64 μg to about 197 μg of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said device provides a mean in-stent late loss in diameter in a human population at 12 months following implantation of less than about 0.5 mm, as measured by quantitative coronary angiography. 6. A drug delivery device according to claim 5 that provides a mean in-stent late loss in diameter in a human population at 12 months following implantation of less than about 0.3 mm, as measured by quantitative coronary angiography. 7. A drug delivery device according to claim 5 or 6 that provides a mean in-stent diameter stenosis in a human population at 12 months following implantation of less than about 22%, as measured by quantitative coronary angiography. 8. A drug delivery device according to claim 7 that provides a mean in-stent diameter stenosis in a human population at 12 months following implantation of less than about 15%, as measured by quantitative coronary angiography. 9. A method of inhibiting neointimal proliferation in a human coronary artery resulting from percutaneous transluminal coronary angioplasty comprising implanting in the lumen of said coronary artery a drug delivery device comprising: an intraluminal stent; a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and from about 64 μg to about 197 μg of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said method provides an in-stent late loss in diameter at 12 months following implantation of less than about 0.5 mm, as measured by quantitative coronary angiography. 10. A method according to claim 9 that provides an in-stent late loss in diameter at 12 months following implantation of less than about 0.3 mm, as measured by quantitative coronary angiography. 11. A method according to claim 9 or 10 that provides an in-stent diameter stenosis at 12 months following implantation of less than about 22%, as measured by quantitative coronary angiography. 12. A method according to claim 11 that provides an in-stent diameter stenosis at 12 months following implantation of less than about 15%, as measured by quantitative coronary angiography. 13. A method of inhibiting neointimal proliferation in a coronary artery resulting from percutaneous transluminal coronary angioplasty comprising implanting in the lumen of said coronary artery a drug delivery device comprising: an intraluminal stent; a biocompatible, nonerodible polymeric coating affixed to the intraluminal stent; and from about 64 μg to about 197 μg of rapamycin or a macrocyclic triene analog thereof that binds FKBP12 incorporated into the polymeric coating, wherein said method provides a mean in-stent late loss in diameter in a human population at 12 months following implantation of less than about 0.5 mm, as measured by quantitative coronary angiography. 14. A method according to claim 13 that provides a mean in-stent late loss in diameter in a human population at 12 months following implantation of less than about 0.3 mm, as measured by quantitative coronary angiography. 15. A method according to claim 13 or 14 that provides a mean in-stent diameter stenosis in a human population at 12 months following implantation of less than about 22%, as measured by quantitative coronary angiography. 16. A method according to claim 15 that provides a mean in-stent diameter stenosis in a human population at 12 months following implantation of less than about 15%, as measured by quantitative coronary angiography. 17. The drug delivery device according to any one of claims 1, 2, 4 or 5 wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 64 μg to about 125 μg. 18. The drug delivery device according to to any one of claims 1, 2, 4 or 5 that releases a portion of said dose of rapamycin or a macrocyclic triene analog thereof at about six weeks following intraluminal implantation. 19. The drug delivery device according to any one of claims 1, 2, 4 or 5 wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 2 μg to about 30 μg per millimeter of stent length. 20. The drug delivery device according to claim 19 wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 3 μg to about 13 μg per millimeter of stent length. 21. The drug delivery device according to claim 19 that releases a portion of said dose of rapamycin or a macrocyclic triene analog thereof at about six weeks following intraluminal implantation. 22. The method according to any one of claims 9, 10, 13 or 14, wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 64 μg to about 125 μg. 23. The method according to any one of claims 9, 10, 13 or 14, wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 2 μg to about 30 μg per millimeter of stent length. 24. The method according to any one of claims 9, 10, 13 or 14, wherein said rapamycin or macrocyclic triene analog thereof is incorporated into the polymeric coating at a dose of from about 3 μg to about 13 μg per millimeter of stent length. 25. The method according to any one of claims 9, 10, 13 or 14, wherein said drug delivery device releases a portion of said dose of rapamycin or a macrocyclic triene analog thereof at about six weeks following intraluminal implantation.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (398)
Hu David Cheng ; Greenfield Alexander Aleksey ; Caggiano Thomas Joseph ; Caufield Craig Eugene, Alkylated rapamycin derivatives.
Domb Abraham J. (Baltimore MD) Shikani Alain (Baltimore MD) Haffer Andrew S. T. (Baltimore MD) Maniar Manoj (Baltimore MD), Anti-infective and anti-inflammatory releasing systems for medical devices.
Greco Ralph S. (Princeton NJ) Harvey Richard A. (East Brunswick NJ) Trooskin Stanley Z. (North Brunswick NJ) Strauss George (Piscataway NJ), Antibiotic bonded prosthesis and process for producing same.
Inoue Kanji (98-13 ; Miyazaki-cho Simogamo Sakyo-ku ; Kyoto-shi ; Kyoto 606 JPX), Appliance collapsible for insertion into human organs and capable of resilient restoration.
Verhoeven Michel (Maastricht NLX) Cahalan Linda L. (Geleen NLX) Hendriks Marc (Hoensbroek NLX) Fouache Benedicte (Maastricht NLX) Cahalan Patrick T. (Geleen NLX), Biocompatability for solid surfaces.
Cahalan Linda L. (Geleen NLX) Cahalan Patrick T. (Geleen NLX) Verhoeven Michel (Maastricht NLX) Hendriks Marc (Hoensbroek NLX) Fouache Benedicte (Maastricht NLX), Biocompatible medical article and method.
Buscemi Paul J. (Long Lake MN) Stejskal Elizabeth A. (St. Paul MN) Palme ; II Donald F. (Dayton MN) Wang Lixiao (St. Paul MN), Biodegradable drug delivery vascular stent.
Buscemi Paul J. (Long Lake MN) Stejskal Elizabeth A. (St. Paul MN) Palme ; II Donald F. (Dayton MN) Wang Lixiao (St. Paul MN), Biodegradable drug delivery vascular stent.
Molnar-Kimber Katherine L. (Glenside PA) Ocain Timothy D. (Waltham MA) Vernon Steven K. (Havertown PA) Huang John J. (San Carlos CA), Biotin esters of rapamycin.
Myler Richard (828 Irwin Dr. Hillsborough CA 94010) Hammerslag Julius G. (27011 Calle Esperanza San Juan Capistrano CA 92675), Cardiovascular stent and retrieval apparatus.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
Cody Wayne Livingston ; Doherty Annette Marian,FRX ; Eaton Scott R. ; Panek Robert Lee, Compounds inhibiting the association of the PDGF receptor and phosphatidylinositol 3-kinase and their use.
Kopia Gregory A. (Phoenixville PA) Horan Paul K. (Downingtown PA) Gray Brian D. (Ardmore PA) Troutner David E. (Phoenixville PA) Muirhead Katharine A. (West Chester PA) Sheth Kamleshkumar A. (Downing, Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles.
Hanson Stephen R. (Stone Mountain GA) Scott Neal A. (Atlanta GA) King ; III Spencer B. (Atlanta GA) Harker Laurence A. (Atlanta GA), Device for local drug delivery and methods for using the same.
Eury Robert P. (Cupertino CA) Garguilo Darlene (Fremont CA) Villareal Plaridel (San Jose CA), Drug loaded polymeric material and method of manufacture.
Heinke Harri (Erlensee DEX) Blatt Wolfgang (Wchtersbach DEX) Busse Bernd (Darmstadt DEX), Electrochemical cell having inflatable seals between electrodes.
Bianco James A. (Seattle WA) Woodson Paul (Bothell WA) Porubek David (Edmonds WA) Singer Jack (Seattle WA), Enatiomerically pure hydroxylated xanthine compounds.
Bianco James A. (Seattle WA) Woodson Paul (Bothell WA) Porubek David (Edmonds WA) Singer Jack (Seattle WA), Enatiomerically pure hydroxylated xanthine compounds.
Bianco James A. (Seattle WA) Woodson Paul (Bothell WA) Porubek David (Edmonds WA) Singer Jack (Seattle WA), Enatiomerically pure hydroxylated xanthine compounds to treat inflammatory diseases.
Bianco James A. (Seattle WA) Woodson Paul (Bothell WA) Porubek David (Edmonds WA) Singer Jack (Seattle WA), Enatiomerically pure hydroxylated xanthine compounds to treat proliferative vascular diseases.
Lazarus Harrison M. (Salt Lake City UT) Williams Ronald G. (Menlo Park CA) Sterman Wesley D. (San Francisco CA), Endovascular grafting apparatus, system and method and devices for use therewith.
Orth Geoffrey A. (La Granada CA) Anderson Scott C. (Sunnyvale CA) Brown Peter S. (Mountain View CA), Expandable stent forming projecting barbs and method for deploying.
Winters Suzanne (Salt Lake City UT) Solen Kenneth A. (Orem UT) Sanders Clifton G. (Salt Lake City UT) Mortensen JD (Sandy UT) Berry Gaylord (Salt Lake City UT), Gas permeable thrombo-resistant coatings and methods of manufacture.
Wu Steven Z. ; Harish Sameer ; Sanders-Millare Deborra ; Guruwaiya Judy A., Implantable medical device having protruding surface structures for drug delivery and cover attachment.
Fox ; Jr. Charles L. (New York NY) Modak Shanta M. (River Edge NJ) Sampath Lester A. (Nyack NY), Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same.
Schwartz Robert S. (Rochester MN) Bresnahan John (Rochester MN) Bergman Rebecca M. (North Oaks MN) Coury Arthur J. (St. Paul MN) Lindell Elaine (Blaine MN) Hull Vincent W. (Fridley MN), Intravascular radially expandable stent.
Schwartz Robert S. (Rochester MN) Bresnahan John (Rochester MN) Bergman Rebecca M. (North Oaks MN) Coury Arthur J. (St. Paul MN) Lindell Elaine (Blaine MN) Hull Vincent W. (Fridley MN) Dror Michael (, Intravascular radially expandable stent.
Schwartz Robert S. (Rochester MN) Bresnahan John (Rochester MN) Bergman Rebecca M. (North Oaks MN) Coury Arthur J. (St. Paul MN) Lindell Elaine (Blaine MN) Hull Vincent W. (Fridley MN) Dror Michael (, Intravascular radially expandable stent.
Schwartz Robert S. ; Bresnahan John ; Bergman Rebecca M. ; Coury Arthur J. ; Lindell Elaine ; Hull Vincent W. ; Dror Michael, Intravascular radially expandable stent.
Fischell Robert E. (Silver Spring MD) Fischell Tim A. (Palo Alto CA), Intravascular stent and percutaneous insertion catheter system for the dilation of an arterial stenosis and the preventi.
Bezwada Rao S. (Whitehouse Station NJ) Arnold Stephen C. (Franklin NJ) Shalaby Shalaby W. (Anderson SC) Williams Bernard L. (Martinsville NJ), Liquid absorbable copolymers for parenteral applications.
Tang Reginald T. (Somerset NJ) Mares Frank (Morris NJ) Boyle ; Jr. William J. (Morris NJ) Chiu Tin-Ho (Essex NJ) Patel Kundan M. (Morris NJ), Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lact.
Tang Reginald T. (Warren NJ) Mares Frank (Whippany NJ) Boyle ; Jr. William J. (Parsippany NJ) Chiu Tin-Ho (Millburn NJ) Patel Kundanbhai M. (Landing NJ), Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lact.
March Keith L. (Carmel IN) Hathaway David R. (Indianapolis IN) Wilensky Robert L. (Indianapolis IN), Method for delivery of smooth muscle cell inhibitors.
Verhoeven Michel (Maastricht NLX) Cahalan Linda L. (Geleen NLX) Hendriks Marc (Hoensbroek NLX) Fouache Benedicte (Hoensbroek NLX) Cahalan Patrick T. (Geleen NLX), Method for making heparinized biomaterials.
Dinh Thomas Q. (5319 Baker Rd. Minnetonka MN) Tuch Ronald J. (12330 51st Ave. N. Plymouth MN) Dror Michael (6227 Westridge Blvd. Edina MN), Method of making an intraluminal stent.
Lee Hai B. (Taejeon KRX) Shin Bung C. (Taejeon KRX) Khang Gilson (Taejeon KRX) Lee Jin H. (Taejeon KRX), Method of manufacturing a vascular graft impregnated with polysaccharide derivatives.
Kinsella James L. (Baltimore MD) Sollott Steven J. (Baltimore MD), Method of treating atherosclerosis or restenosis using microtubule stabilizing agent.
Morris Randall Ellis (Los Altos CA) Gregory Clare Robert (Menlo Park CA), Method of treating hyperproliferative vascular disease with rapamycin and mycophenolic acid.
Maraganore John M. (Concord MA) Fenton ; II John W. (Malden Bridge NY) Kline Toni (Cambridge MA), Methods for coating invasive devices with inhibitors of thrombin.
Martinson Laura A. (Lake Villa IL) Brauker James H. (Lake Villa IL) Johnson Robert C. (Bartlett IL) Loudovaris Thomas (Grayslake IL), Methods for enhancing vascularization of implant devices.
Fischell Robert E. (14600 Viburnum Dr. Dayton MD 21036) Fischell David R. (71 Riverlawn Dr. Fair Haven NJ 07704) Fischell Tim A. (1018 Chancery Dr. Nashville TN 37215), Multi-cell stent with cells having differing characteristics.
Winters Suzanne (Salt Lake City UT) Solen Kenneth A. (Orem UT) Sanders Clifton G. (Salt Lake City UT) Mortensen J. D. (Sandy UT) Berry Gaylord (Salt Lake City UT), Multifunctional thrombo-resistant coatings and methods of manufacture.
Winters Suzanne (Salt Lake City UT) Solen Kenneth A. (Orem UT) Sanders Clifton G. (Salt Lake City UT) Mortensen J. D. (Sandy UT) Berry Gaylord (Salt Lake City UT), Multifunctional thrombo-resistant coatings and methods of manufacture.
Friesen Dwayne T. (Bend OR) Newbold David D. (Bend OR) McCray Scott B. (Bend OR) Ray Roderick J. (Bend OR), Pervaporation by countercurrent condensable sweep.
Hoffman Allan S. (King County WA) Garfinkle Andrew (King County WA) Ratner Buddy D. (King County WA) Hanson Stephen R. (San Diego County CA), Plasma gas discharge treatment for improving the biocompatibility of biomaterials.
Hoffman Allan S. (Seattle WA) Garfinkle Andrew M. (Montreal WA CAX) Ratner Buddy D. (Seattle WA) Hanson Stephen R. (Encinitas CA), Plasma gas discharge treatment for improving the compatibility of biomaterials.
Tartaglia Joseph M. (Redwood City CA) Loeffler Joseph P. (Mountain View CA) Turnlund Todd H. (Mountain View CA), Polymer film for wrapping a stent structure.
Tartaglia Joseph M. (Redwood City CA) Loeffler Joseph P. (Mountain View CA) Turnlund Todd H. (Mountain View CA), Polymer film for wrapping a stent structure.
Feijen Jan (Hengelo NLX) Engbers Gerardus H. M. (Oldenzaal NLX), Process for activating a polymer surface for covalent bonding for subsequent coating with heparin or the like.
Larm Olle (Nyngsvgen 86 S-161 39 Bromma SEX), Process for covalent coupling for the production of conjugates, and polysaccharide containing products thereby obtained.
Bianco James A. (Seattle WA) Woodson Paul (Bothell WA) Porubek David (Edmonds WA) Singer Jack (Seattle WA), Process for preparing enantiomerically pure xanthine derivatives.
Hsu Li-Chien (Mission Viejo CA) Balding David P. (Mission Viejo CA) Farhat Lawrence (Carlsbad CA), Process for reducing the thrombogenicity of biomaterials.
Balko Alexander B. (30 Red Barn La. East Greenwich RI 02818) Shah Dhiraj M. (R.D. #1 ; Rte. 43 Rensselaer NY 12144), Process for restoring patency to body vessels.
Larm Karl O. P. (Bromma SEX) Adolfsson Lars A. (Uppsala SEX) Olsson Kjell P. (Uppsala SEX), Process for the preparation of surface modified solid substrates.
Larm Karl O. P. (Bromma SEX) Adolfsson Lars A. (Uppsala SEX) Olsson Kjell P. (Uppsala SEX), Process for the preparation of surface modified solid substrates.
Narayanan Pallassana V. (Davie FL) Stanley Kimberly D. (Florida City FL), Radiofrequency plasma treated polymeric surfaces having immobilized anti-thrombogenic agents.
Narayanan Pallassana V. (Davie FL) Stanley Kimberly D. (Florida City FL), Radiofrequency plasma treated polymeric surfaces having immobilized anti-thrombogenic agents.
Clackson Timothy P. ; Gilman Michael Z. ; Holt Dennis A. ; Keenan Terence P. ; Rozamus Leonard ; Yang Wu, Regulation of biological events using novel compounds.
Williams Simon F. ; Martin David P. ; Gerngross Tillman ; Horowitz Daniel M., Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation.
Sydney Gregory T. ; Seiber Russ ; Madenjian Arthur R. ; Belovi Annette, Selective coating of a balloon catheter with lubricious material for stent deployment.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Mayer David W. (Bloomington MN) Gilman Byron L. (Plymouth MN) Walgren Susan M. (Shoreview MN) Berglund June M. (Forest Lake MN), Soluble covering for cardiac pacing electrode.
Fischell Robert E. (14600 Viburnum Dr. Dayton MD 21036) Fischell David R. (71 Riverlawn Dr. Fair Haven NJ 07704) Fischell Tim A. (1018 Chancery La. Nashville TN 37215), Stent having a multiplicity of closed circular structures.
Scott Neal A. (Atlanta GA) Hanson Stephen R. (Stone Mountain GA) King ; III Spencer B. (Atlanta GA) Harker Laurence A. (Atlanta GA), Stent sheath for local drug delivery.
Wang Lixiao (Maple Grove MN) Willard Martin R. (Maple Grove MN) Tran Thomas T. (Coon Rapids MN) Hastings Roger (Maple Grove MN) Schmaltz Dale F. (Boulder CO) Holman Thomas J. (Minneapolis MN), Temporary stent.
Schmaltz Dale F. (St. Paul MN) Walter Larry (Maple Grove MN) Holman Thomas (Minneapolis MN) Kostur Gary (New Hope MN), Temporary stent and methods for use and manufacture.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GB2 ; Metcalfe James C.,GB2 ; Weissberg Peter L.,GB2 ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Fearnot Neal E. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees ; III William D. (West Lafayette IN), Thrombolytic treated intravascular medical device.
Bianco James A. (Seattle WA) Woodson Paul (Bothell WA) Porubek David (Edmonds WA) Singer Jack (Seattle WA), Treatment of diseases using enantiomerically pure hydroxylated xanthine compounds.
Narayanan Pallassana V. (Davie FL) Rowland Stephen M. (Miami FL) Stanley Kimberly D. (Miami FL), Treatment of metallic surfaces using radiofrequency plasma deposition and chemical attachment of bioactive agents.
Dardik Herbert (270 Highwood Ave. Tenafly NJ 07670) Dardik Irving I. (Hillcrest Rd. Great Meadows NJ 07838), Tubular prostheses for vascular reconstructive surgery and process for preparing same.
Dardik Herbert (270 Highwood Ave. Tenafly NJ 07670) Dardik Irving I. (Hillcrest Rd. Great Meadows NJ), Tubular prosthesis for vascular reconstructive surgery and process for preparing same.
Ohlstein Eliot H. (Glenmoore PA), Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell pr.
Ohlstein Eliot H. (Glenmoore PA), Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell pr.
Yue Tian-Li (Havertown PA) Ohlstein Eliot H. (Glenmoore PA) Feuerstein Giora Z. (Wynnewood PA), Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and prolifer.
Simpson John B. (Menlo Park CA) Robert Edward W. (Los Altos CA), Vascular guiding catheter assembly and vascular dilating catheter assembly and a combination thereof and methods of maki.
Ferren, Bran; Hagen, Jeffrey John; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Circulatory monitoring systems and methods.
Ferren, Bran; Hagen, Jeffrey John; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Circulatory monitoring systems and methods.
Ferren, Bran; Hagen, Jeffrey John; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Circulatory monitoring systems and methods.
Ferren, Bran; Hagen, Jeffrey John; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Circulatory monitoring systems and methods.
Falotico, Robert; Siekierka, John; Llanos, Gerard H.; Kopia, Gregory A.; Carter, Andrew J., Drug/drug delivery systems for the prevention and treatment of vascular disease.
Ferren, Bran; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Treatment indications informed by a priori implant information.
Ferren, Bran; Hyde, Roderick A.; Ishikawa, Muriel Y.; Leuthardt, Eric C.; Rivet, Dennis J.; Wood, Jr., Lowell L.; Wood, Victoria Y. H., Treatment indications informed by a priori implant information.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.